Aggressive Plasmablastic Myeloma With Extramedullary Cord Compression and Hyperammonemic Encephalopathy: Case Report and Literature Review

被引:4
作者
Dah, Kingsley [1 ]
Lavezo, Jonathan L. [2 ]
Dihowm, Fatma [1 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr El Paso, Dept Internal Med, El Paso, TX 79905 USA
[2] Texas Tech Univ, Hlth Sci Ctr El Paso, Dept Pathol, El Paso, TX USA
关键词
Multiple myeloma; plasmablastic myeloma; spinal cord compression; hyperammonemic encephalopathy; MULTIPLE-MYELOMA; PRESENTING FEATURE; PROGNOSTIC-FACTOR; BORTEZOMIB; SURVIVAL; THERAPY; SPINE;
D O I
10.21873/anticanres.15403
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Plasmablastic myeloma is an aggressive subtype of multiple myeloma with overall poor prognosis. Spinal cord compression and hyperammonemic encephalopathy are two grave complications of multiple myeloma with significantly poor survival outcomes. Case Report: A 49-year-old male presented with a 5-day history of worsening abdominal distention with inability to walk, urinate or defecate. Imaging findings of innumerable spinal osteolytic lesions with paraspinal masses coupled with a bone marrow biopsy of >= 70% plasmablasts confirmed the diagnosis of plasmablastic myeloma. Despite spinal decompression surgery, the patient remained paraplegic. Three myeloma-directed chemotherapies failed, eventually leading to him developing hyperammonemic encephalopathy culminating in his death. Conclusion: Plasmablastic myeloma is a rare entity which poses therapeutic challenges especially in patients with negative prognosticators, including high-risk cytogenetic markers, extraosseous involvement with cord compression and hyperammonemic encephalopathy. Early aggressive management with consideration of novel therapeutic alternatives, especially in treatment refractory disease, can be worthwhile.
引用
收藏
页码:5839 / 5845
页数:7
相关论文
共 36 条
[1]   Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value [J].
An, Gang ;
Xu, Yan ;
Shi, Lihui ;
Zhong, Shizhen ;
Deng, Shuhui ;
Xie, Zhenqing ;
Sui, Weiwei ;
Zhan, Fenghuang ;
Qiu, Lugui .
HAEMATOLOGICA, 2014, 99 (02) :353-359
[2]   Simultaneous double hemodialysis for the control of refractory hyperammonemia [J].
Brucculeri, Michael ;
Gabbard, Wesley ;
Masson, John ;
Jooma, Nuruddin .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2013, 36 (02) :135-138
[3]   Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy [J].
Cichoz-Lach, Halina ;
Michalak, Agata .
WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (01) :26-34
[4]   Defining and Managing High-Risk Multiple Myeloma: Current Concepts [J].
Costa, Luciano J. ;
Usmani, Saad Z. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (12) :1730-1737
[5]   Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center [J].
Damaj, G ;
Mohty, M ;
Vey, N ;
Dincan, E ;
Bouabdallah, R ;
Faucher, C ;
Stoppa, AM ;
Gastaut, JA .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 73 (06) :402-406
[6]  
Dürr HR, 2002, SPINE, V27, P320
[7]   Hyperammonemic encephalopathy as the presenting feature of multiple myeloma [J].
Fernandez-Alvarez, Ruben ;
Gonzalez-Garcia, Esther ;
Fernandez-Alvarez, Carmen .
MEDICINA CLINICA, 2016, 147 (10) :472-473
[8]   Plasmablastic morphology - An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group [J].
Greipp, PR ;
Leong, T ;
Bennett, JM ;
Gaillard, JP ;
Klein, B ;
Stewart, JA ;
Oken, MM ;
Kay, NE ;
Van Ness, B ;
Kyle, RA .
BLOOD, 1998, 91 (07) :2501-2507
[9]   Multiple Myeloma and Epidural Spinal Cord Compression : Case Presentation and a Spine Surgeon's Perspective [J].
Ha, Kee-Yong ;
Kim, Young-Hoon ;
Kim, Hyun-Woo .
JOURNAL OF KOREAN NEUROSURGICAL SOCIETY, 2013, 54 (02) :151-154
[10]   A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM) [J].
Harrison, Simon J. ;
Minnema, Monique C. ;
Lee, Hans C. ;
Spencer, Andrew ;
Kapoor, Prashant ;
Madduri, Deepu ;
Larsen, Jeremy ;
Ailawadhi, Sikander ;
Kaufman, Jonathan L. ;
Raab, Marc S. ;
Hari, Parameswaran ;
Iida, Shinsuke ;
Vij, Ravi ;
Davies, Faith E. ;
Lesley, Robin ;
Upreti, Vijay V. ;
Yang, Zhao ;
Sharma, Anjali ;
Minella, Alex ;
Lentzsch, Suzanne .
BLOOD, 2020, 136